EFG Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

EFG Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-41,844	Closed	-$2.94M	–	180
2024 Q3	$2.94M	Sell	41,844 -35,646	-46%	-$2.98M	0.49%	73
2024 Q2	$6.38M	Buy	77,490 +355	+0.5%	+$29.6K	1.11%	14
2024 Q1	$6.74M	Buy	77,135 +7,519	+11%	+$673K	1.16%	11
2023 Q4	$6.71M	Buy	69,616 +2,294	+3%	+$203K	1.27%	10
2023 Q3	$5.96M	Buy	67,322 +20,874	+45%	+$1.86M	1.41%	6
2023 Q2	$4.03M	Buy	46,448 +35,840	+338%	+$3.37M	0.86%	43
2023 Q1	$1.03M	Buy	10,608 +484	+5%	+$50.2K	0.23%	149
2022 Q4	$1.04M	Sell	10,124 -197	-2%	-$18.5K	0.23%	147
2022 Q3	$875K	Buy	+10,321	New	+$919K	0.2%	153

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

EFG Asset Management's BMRN Position: Q4 2024 in Review

EFG Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 41,844 shares — an estimated $2.94M sold.

EFG Asset Management first reported a position in BMRN in Q3 2022 and held it in 9 quarters. The position peaked at $6.74M in Q1 2024. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

EFG Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
EFG Asset Management sold 41,844 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $2.94M.
EFG Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2022 and held it in 9 quarters.
EFG Asset Management's BioMarin Pharmaceuticals position peaked at $6.74M in Q1 2024.
543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on EFG Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.